We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Clinical RNA Sequencing Platform Can Improve Rare Disease Diagnostics in Pediatrics

By LabMedica International staff writers
Posted on 17 Apr 2023

RNA sequencing offers an alternative perspective on genes by examining how the body interprets the genetic code rather than focusing solely on the code itself. More...

DNA-based tests like genome sequencing capture an individual's genetic code, but analyzing RNA, which carries protein-building instructions, can improve scientists' understanding of how DNA is being interpreted. Now, a new clinical RNA sequencing platform is aiding research into rare genetic conditions.

Over the past six years, scientists at The Hospital for Sick Children (SickKids, Toronto, ON, Canada) have worked on integrating RNA sequencing into their research pipeline. This technology has now become the first validated RNA sequencing platform in Canada for use in clinical settings as a precision diagnostic tool. Using this platform, the scientists conducted genome and RNA sequencing on 97 individuals from 39 different families. The RNA analysis provided additional diagnostic information for 8% of patients whose diagnoses were not confirmed through genome sequencing alone, either confirming or ruling out the impact of a DNA variant identified during genome sequencing.

The study is also among the first to explore the utility of a trio-approach to RNA sequencing, which involves performing RNA sequencing on the affected individual and both parents. Although trio RNA sequencing did not reveal any new genetic variants in this population, it reduced the time researchers spent reviewing results and increased analysis efficiency. As more research is conducted into RNA sequencing's benefits, scientists and clinicians are eager to further delineate the situations in which clinical RNA sequencing can offer valuable insights for patients with rare genetic conditions and other patient groups. Establishing this evidence will be crucial for informing decisions about making RNA sequencing more widely available for precision diagnostics.

“We hope that the results of our study will help support the inclusion of clinical based RNA-testing in diagnostic workflows for children with rare conditions,” said co-leads and physician-scientists Drs. Gregory Costain and Jim Dowling.

“By carefully sequencing and analyzing RNA from diverse populations of sick and healthy children we have the potential to improve how we find diagnoses for patients with rare genetic conditions,” said senior scientist Dr. Michael Wilson.

Related Links:
SickKids 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.